Lacosamida y dolor neuropático, una revisión

Alcántara-Montero, A.; Sánchez-Carnerero, C.I.

doi:10.33588/rn.6205.2015498

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly; other studies reported as much as 30-50% relief in neuropathic pain with Lacosamide. 1,14 Further; we did not find any significant pain relief with placebo effect which Shaibani and coworkers 11 claimed. Other studies also evaluated 200 and 600 mg/ day doses but found 400 mg more effective and safe.…”

Section: Discussioncontrasting

confidence: 48%

Role of Lacosamide in Diabetic Neuropathy: An Experience at Tertiary Care Hospital in Rural Sindh

Rehman¹,

Ahmed²,

Mujtaba³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: Lacosamide is a relatively newer drug for treatment of chronic diabetic painful neuropathy (CDPN). Objective: To analyse the effectiveness and safety of lacosamide in patients with diabetic neuropathy. Study Design: Randomized controlled clinical trial. Duration and Place of Study: This study was conducted at department of neurology, Khairpur Medical College, Khairpur Mir’s, during from the period Oct 2021 to March 2022. Methodology: Ninety-two patients of either gender, age 20-60 years, known case of diabetes mellitus for minimally 5 years having pain intensity in the range of 4-9 on 11-point (0–10) numerical rating scale & HbA1c value 6.1%-10% were included and assigned randomly (Lacosamide = 46 & Placebo = 46) after taking a valid informed/ written consent. Lacosamide 400 mg/ day was given upto 20 weeks which initially increased from baseline at rate of 100 mg per week. The primary outcome variable was changes from baseline in average pain scores. Results: The mean age of lacosamide group was 40.26±11.33 while in placebo group was 41.30±10.46 years. The mean Pretrial Pain Score measured on NRS of lacosamide group was 6.59±1.95 which decreased to 3.39±1.94 and in placebo group was 6.71±1.89 which decreased to 6.35±1.52 by the end of maintenance phase (20 weeks; p<0.0001). Adverse events (59%) of the patients experience adverse events at least for 1 time. Common side-effects included headache (11% vs. 31%), dizziness (09% vs. 11%), nausea (15% vs. 8%), and diarrhea (8% vs. 19%) with lacosamide and placebo group respectively each (p<0.0001). Conclusion: Lacosamide is a safe and effective drug and achieved in pain relief and may be prescribed as routine treatment of chronic diabetic painful neuropathy. Keywords: Diabetes mellitus, Pain, Chronic diabetic painful neuropathy, Lacosamide, Numerical rating scale

show abstract

Section: Discussioncontrasting

confidence: 48%

Role of Lacosamide in Diabetic Neuropathy: An Experience at Tertiary Care Hospital in Rural Sindh

Rehman¹,

Ahmed²,

Mujtaba³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…We found the randomized, double-blind, placebocontrolled and phenotype-stratified trial on the effect of lacosamide (LCM) in peripheral neuropathic pain (NP) published by Carmland and colleagues highly interesting (Carmland et al, 2023). Although the primary objective of the trial was not achieved (better effect of LCM in the irritable nociceptor phenotype compared with the non-irritable nociceptor), this work is worthy of our acknowledgement because, up to now, most of the available evidence on LCM for NP, except for the phase II/III trials done on diabetic neuropathy (PDN), has come from open and observational studies conducted without a control group and with a limited number of patients (Alcántara Montero & Sánchez Carnerero, 2016).…”

Section: E T T E R T O T H E E D I T O Rmentioning

confidence: 99%

“…Few patients with PDN treated with LCM (just 5%) were included in this trial. With the exception of trigeminal neuralgia (TN), the results attained for other NP models are inconclusive (Alcántara Montero & Sánchez Carnerero, 2016). In this regard, the positive results recently obtained with LCM in patients with refractory first-line treatment TN are remarkable, in terms of both efficacy and safety.…”

Section: E T T E R T O T H E E D I T O Rmentioning

confidence: 99%

Comment on ‘The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial’ by Carmland et al.

Alcántara Montero,

Pacheco de Vasconcelos

2023

European Journal of Pain

View full text Add to dashboard Cite

“…Recently, there has been a growing interest in new drugs that act by blocking voltage‐gated sodium channels, 8,9 similar to carbamazepine or oxcarbazepine, but with novel mechanisms of action that may decrease the very common side effects of these drugs 10 . For instance, lacosamide blocks voltage‐gated sodium channels in a slow inactivating manner 11 and has recently shown efficacy in the treatment of neuropathic pain 12,13 . Its potential effectiveness as an intravenous treatment for acute pain exacerbations of TN has recently been described in a retrospective study of 63 cases, 14 but only small case series have suggested its use as an oral adjunctive therapy in refractory TN 15–17 .…”

Section: Introductionmentioning

confidence: 99%

“…10 For instance, lacosamide blocks voltage-gated sodium channels in a slow inactivating manner 11 and has recently shown efficacy in the treatment of neuropathic pain. 12,13 Its potential effectiveness as an intravenous treatment for acute pain exacerbations of TN has recently been described in a retrospective study of 63 cases, 14 but only small case series have suggested its use as an oral adjunctive therapy in refractory TN. [15][16][17] Nevertheless, and given the absence of alternatives after first-line treatments have failed, many neurologists prescribe lacosamide off-label, trying to help these patients with refractory TN.…”

mentioning

confidence: 99%

Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: First-line treatment for trigeminal neuralgia (TN) is limited to carbamazepine and oxcarbazepine, and in refractory cases, alternatives are scarce.Lacosamide has been suggested as a valid option. In this study, we describe a series of patients who received oral lacosamide as treatment for TN after first-line drug failure. Methods:In this retrospective descriptive cohort study, we included patients with refractory TN who attended a tertiary center between 2015 and 2021 and were prescribed oral lacosamide after first-line treatment failure. The primary endpoints were pain relief and adverse effects. We secondarily analyzed clinical outcomes and compared responders versus nonresponders in the search for potential predictors of response.Results: Eighty-six patients were included (mean age: 62 [SD 15.6] years; 54/86 [63%] female). The TN etiology was secondary in 16/86 (19%) patients. Concomitant continuous pain was present in 29/86 (34%) patients. The mean number of previous treatments was 2.7 [SD 1.5]. Pain relief was achieved in 57/86 (66%) cases, with 28/86 (33%) patients presenting adverse effects, all of which were mild. No statistically significant differences were observed between responders and nonresponders, but subtle clinical differences suggested potential predictors of response. Conclusion:Lacosamide may be an effective and relatively safe treatment for refractory pain in TN patients after first-line treatment failure.

show abstract

Lacosamida y dolor neuropático, una revisión

Cited by 9 publications

References 0 publications

Role of Lacosamide in Diabetic Neuropathy: An Experience at Tertiary Care Hospital in Rural Sindh

Role of Lacosamide in Diabetic Neuropathy: An Experience at Tertiary Care Hospital in Rural Sindh

Comment on ‘The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial’ by Carmland et al.

Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases

Contact Info

Product

Resources

About